Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: a randomised multicentre trial

@article{Saunders1997ContinuousHA,
  title={Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: a randomised multicentre trial},
  author={M. Saunders and S. Dische and A. Barrett and Angela Harvey and on behalf of the Chart Steering Committee},
  journal={The Lancet},
  year={1997},
  volume={350},
  pages={161-165}
}
  • M. Saunders, S. Dische, +2 authors on behalf of the Chart Steering Committee
  • Published 1997
  • Medicine
  • The Lancet
    • BACKGROUND Human tumour cells can proliferate rapidly, and giving radiotherapy in many small fractions may reduce long-term normal-tissue morbidity. [...] Key Method We included patients with NSCLC localised to the chest with a performance status of 0 or 1 in whom radical radiotherapy was chosen as the definitive management. Patients were randomly allocated in a 3:2 ratio to CHART or conventional radiotherapy. The latter was thirty fractions of 2 Gy to a total dose of 60 Gy in 6 weeks. Expand Abstract
    View on Elsevier
    uio.no
    540 Citations
    Highly Influential Citations
    8
    Background Citations
    70
    Methods Citations
    13
    Results Citations
    10
    540 Citations
    Citation Type

    Citation Type

    Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multicentre trial. CHART Steering committee.
    • 452
    Accelerated radical radiotherapy for non-small cell lung cancer using two common regimens: a single-centre retrospective study of outcome.
    • 19
    Continuous Hyperfractionated Accelerated Radiotherapy (CHART) for Non-small Cell Lung Cancer (NSCLC): 7 Years' Experience From Nine UK Centres.
    • 2
    Very low acute toxicity of three fractions per day accelerated radiotherapy given after induction chemotherapy and surgery in stage III non-small cell lung cancer.
    • 3
    Induction chemotherapy and continuous hyperfractionated accelerated radiotherapy (chart) for patients with locally advanced inoperable non-small-cell lung cancer: the MRC INCH randomized trial.
    • 29
    Escalated dose for non-small-cell lung cancer with accelerated hypofractionated three-dimensional conformal radiation therapy.
    • 52
    73.6 Gy and beyond: hyperfractionated, accelerated radiotherapy for non-small-cell lung cancer.
    • 79
    Continuous hyperfractionated accelerated radiation therapy week-end less in combination with neoadjuvant chemotherapy for the treatment of stage III non-small-cell lung cancer.
    • 8
    SPLIT-COURSE ACCELERATED HYPERFRACTIONATED RADIOTHERAPY IN HEAD AND NECK CARCINOMA- AN EXPERIENCE IN TERMS OF LOCAL TUMOUR CONTROL AND TOXICITY
    Programming of radiotherapy in the treatment of non-small-cell lung cancer--a way to advance care.
    • 6

    References

    SHOWING 1-10 OF 23 REFERENCES
    Randomised multicentre trials of CHART vs conventional radiotherapy in head and neck and non-small-cell lung cancer: an interim report. CHART Steering Committee.
    • 164
    • PDF
    Continuous, hyperfractionated, accelerated radiotherapy (CHART) in non-small cell carcinoma of the bronchus.
    • 104
    Costs of conventional radical radiotherapy versus continuous hyperfractionated accelerated radiotherapy (CHART) in the treatment of patients with head and neck cancer or carcinoma of the bronchus. Medical Research Council CHART Steering Committee.
    • D. Coyle, M. Drummond
    • Medicine
    • Clinical oncology (Royal College of Radiologists (Great Britain))
    • 1997
    • 26
    Thoracic radiation therapy alone compared with combined chemoradiotherapy for locally unresectable non-small cell lung cancer. A randomized, phase III trial.
    • 184
    Is control of the primary tumour worthwhile in non-oat cell carcinoma of the bronchus?
    • M. Saunders
    • Medicine
    • Clinical oncology (Royal College of Radiologists (Great Britain))
    • 1991
    • 9
    Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials
    • 2,609
    Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer.
    • 655
    Long‐term observations of the patterns of failure in patients with unresectable non‐oat cell carcinoma of the lung treated with definitive radiotherapy report by the radiation therapy oncology group
    • 558
    Radiotherapy as an alternative to surgery in elderly patients with resectable lung cancer.
    • 214
    Non-small-cell lung cancer: should unresectable stage III patients routinely receive high-dose radiation therapy?
    • D. G. Payne
    • Medicine
    • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    • 1988
    • 56